Drug Profile

AMT 143

Alternative Names: AMT-143

Latest Information Update: 10 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AmacaThera
Class Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
Mechanism of Action Potassium channel antagonists; Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Postoperative pain

Most Recent Events

04 Nov 2025 Pacira BioSciences enters into an exclusive license agreement with AmacaThera for AMT 143 for Postsurgical pain control
04 Nov 2025 AmacaThera plans the phase II clinical program for AMT 143 in 2026
25 Sep 2025 AMT 143 is still in phase I clinical trials in Postoperative pain (AmacaThera pipeline, September 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com